Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effects of subantimicrobial dose doxycycline (50
mg/d), administered for 12 wk, for patients with active moderate-severe Graves' Orbitopathy
(GO).